OncoCyte Corporation

OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

The company believes that better and earlier detection of cancer through liquid biopsies will:

  • Improve patient outcomes
  • Increase the life expectancy of cancer patients
  • Significantly reduce health care costs

Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.

These invasive tests are expensive, time-consuming when time may be of utmost importance, and lead to both patient anxiety and physician uncertainty about the diagnosis.

Our next generation liquid biopsy diagnostics will use blood or urine samples to detect the presence or absence of cancer. These diagnostics are:

  • Simple
  • Accurate
  • Fast
  • Non-invasive

OncoCyte’s initial focus is on cancers with large patient populations and significant unmet need.

Company Growth (employees)
Alameda, US
Size (employees)
15 (est)
OncoCyte Corporation is headquartered in Alameda, US

OncoCyte Corporation Office Locations

OncoCyte Corporation has an office in Alameda
Alameda, US (HQ)
102 1010 Atlantic Ave

OncoCyte Corporation Financials and Metrics

OncoCyte Corporation Financials


Market capitalization (08-Dec-2017)

160.9 m
OncoCyte Corporation's current market capitalization is $160.9 m.
USDFY, 2016

R&D expense

5.7 m

General and administrative expense

5.5 m

Operating expense total

11.1 m


(11.1 m)
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Sales and marketing expense

655 k477 k

R&D expense

1.7 m1.2 m1.4 m1.8 m2 m

General and administrative expense

1.2 m1.3 m1.2 m2 m1.1 m

Operating expense total

2.9 m(2.5 m)(2.6 m)4.5 m(3.6 m)(6.8 m)
USDFY, 2016


10.2 m

Accounts Receivable

14.3 m


285 k

Current Assets

12.7 m
USDQ3, 2017


457 k
    USDFY, 2016

    Net Income

    (11.2 m)

    Depreciation and Amortization

    145 k


    101 k

    Cash From Operating Activities

    (7.5 m)
    USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    (2.9 m)(2.5 m)(2.6 m)(4.7 m)


    457 k

    Accounts Payable

    403 k192 k870 k211 k
      Show all financial metrics

      OncoCyte Corporation Operating Metrics

      FY, 2016

      Patents Issued


      Patents and Patent Applications

      Show all operating metrics

      OncoCyte Corporation Market Value History

      OncoCyte Corporation's Web-traffic and Trends

      OncoCyte Corporation Online and Social Media Presence

      OncoCyte Corporation Company Life and Culture

      You may also be interested in